QIAGEN (QGEN)
(Delayed Data from NYSE)
$46.36 USD
+0.79 (1.73%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.36 USD
+0.79 (1.73%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome
by Zacks Equity Research
QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Qiagen (QGEN) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.
QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio
by Zacks Equity Research
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.
QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer
by Zacks Equity Research
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
by Zacks Equity Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.
Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.
DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged
by Zacks Equity Research
Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.
Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.
LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The robust year-over-year revenue growth across Thermo Fisher's (TMO) Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.
West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.
Align Technology (ALGN) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
Robust Clear Aligner case volume growth and increased uptake of the iTero Element 5D Plus are driving Align Technology's (ALGN) first-quarter top line.